Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Champion Industries, Inc. (OTC: CHMP).

Full DD Report for CHMP

You must become a subscriber to view this report.

Recent News from (OTC: CHMP)

Your Daily Pharma Scoop: Omeros' Omidria, Titan Signs Agreement, Reata Announces Top-Line Results
Analysis focus: Omeros Today we will discuss Omeros (NASDAQ: OMER ), which has surged on the back of an update for its approved product Omidria. We discussed the pass through situation with Omidria in an article late last year. As we noted, Omidria was expected to lose its separate ...
Source: SeekingAlpha
Date: March, 23 2018 00:49
Your Daily Pharma Scoop: Clovis Oncology Gets A Boost, Mesoblast Positive Data, Kadmon's Updated Results
Analysis of top Seeking Alpha coverage: Clovis Oncology Today we will discuss Clovis Oncology ( CLVS ). Clovis Oncology have had a good run this week, gaining more than 11%. The stock though still remains down more than 21% in the last six months and well-off its 52-week high of $99.45. T...
Source: SeekingAlpha
Date: February, 24 2018 08:00
Your Daily Pharma Scoop: Portola Update, Wave Life Sciences To Collaborate With Takeda, AbbVie Reports Data For Egolix
Analysis of top Seeking Alpha coverage: Portola Pharmaceuticals Today we will discuss Portola Pharmaceuticals ( PTLA ), which came out with some mixed news. PTLA shares were down sharply at the time of writing this note. Portola reported that the European Medicines Agency’s ((EM...
Source: SeekingAlpha
Date: February, 21 2018 11:49
Your Daily Pharma Scoop: Lipocine's Gloomy Future, Puma Labeling Change, Concert's Mixed Day
Today we will discuss the Ad Com's vote against Lipocine's ( LPCN ) TLANDO. The news sparked a huge sell-off in LPCN on Wednesday. Few days before the Ad Com, we had written a note on LPCN, highlighting that it is a binary event. TLANDO had been rejected by the FDA in 2016, which pushed LPCN...
Source: SeekingAlpha
Date: January, 13 2018 08:00
Your Daily Pharma Scoop: Ultragenyx Sells Voucher, Regeneron Announces Collaboration, Madrigal Offering
Content Analysis of coverage: RARE Stocks in the news: REGN, MDGL Analyst Ratings Insider Sales Insider Purchases Earnings Report Secondary Offerings Earnings Calendar Subscriber Questions & Answers (for TPT Subscribers only) Catalyst Rundown (for...
Source: SeekingAlpha
Date: December, 19 2017 08:04
Your Daily Pharma Scoop: Aclaris Gets Approval, Egalet Surges, Alnylam Gains As FDA Lifts Clinical Hold
Content Analysis of coverage: ACRS Stocks in the news: EGLT, TSRO Analyst Ratings Insider Sales Insider Purchases Earnings Report Secondary Offerings Earnings Calendar Daily Trade Idea: (for TPT Subscribers only) Subscriber Questions & Answers (for T...
Source: SeekingAlpha
Date: December, 17 2017 16:15
Your Daily Pharma Scoop: Omeros Potential, Portola's Setback, Proteostasis Soars
Content Analysis of coverage Stocks in the news Analyst Ratings Insider Sales Insider Purchases Earnings Report Secondary Offerings Earnings Calendar TPT subscribers only Trade Idea of the Day Subscriber Questions & Answers Catalyst Ru...
Source: SeekingAlpha
Date: December, 13 2017 06:43
Your Daily Pharma Scoop: Portola Upside, Novartis Reports Positive Cosentyx Data, Keryx Tumbles
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Portola Today we will disc...
Source: SeekingAlpha
Date: November, 09 2017 03:26
European advisory committee rejects AB Science's masitinib marketing application for mastocytosis; shares down 26%
The European Medicines Agency's Committee for Medicinal Products for Human Use ( CHMP ) adopts a negative opinion regarding AB Sciences' ( OTCPK:ABSCF -26.3% ) marketing application seeking approval of masitinib for the treatment of adult patients with smoldering or indolent systemic sev...
Source: SeekingAlpha
Date: May, 17 2017 13:36
Biotech Forum Daily Digest: Is Biotech On The Rebound? Medivation On The Block? Agenus In The Spotlight
The biotech sector greeted trading in the second quarter like a flower welcomes the spring. Biotech rose nearly three percent in the first trading day of April as frost finally feels like it is melting on this beaten down and oversold area of the market. Combined with Thursday's large gains, t...
Source: SeekingAlpha
Date: April, 04 2016 08:57


About Champion Industries, Inc. (OTC: CHMP)

Logo for Champion Industries, Inc. (OTC: CHMP)

A major commercial printer, business form manufacturer and supplier of office products and office furniture.


Contact Information



Current Management

  • Adam M. Reynolds / President, CEO
    • Mr. Reynolds brings a diverse and intimate knowledge of the Company s operations to the principal executive position and has been with the Company since serving in various capacities including assistant to the Company s former President and Chief Operating Officer , Division Manager of the Company s Champion Graphic Communications division in Baton Rouge, LA , and, more recently, Division Manager of the Company s Chapman Printing division in Parkersburg, WV in concurrence with the Director of Information Technology. Mr. Reynolds also holds a degree in finance from Virginia Tech University.
  • Justin Evans / CFO
  • Walter R. Sansom / Secretary
  • Greg Adkins / Controller
  • Marshall T. Reynolds / Chairman

Current Share Structure

  • Market Cap: $949,569 - 03/13/2018
  • Authorized: 25,000,000 - 03/13/2018
  • Issue and Outstanding: 55,857 - 03/13/2018


Recent Filings from (OTC: CHMP)

Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: August, 05 2016
Certification of termination of registration of a class of security under Section 12(g) or notice of suspension of duty to file reports under Section 13 and 15(d) of the Act Section 12 (g).
Filing Type: 15-12GFiling Source: edgar
Filing Date: July, 28 2016
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: July, 28 2016
Amendment to the schedule
Filing Type: SC 13E3/AFiling Source: edgar
Filing Date: July, 28 2016
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: July, 14 2016
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: July, 05 2016
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: June, 14 2016
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: May, 31 2016
Proxy soliciting materials. Revised preliminary material
Filing Type: PRER14AFiling Source: edgar
Filing Date: May, 25 2016
Correspondence from the Filer to the SEC
Filing Type: CORRESPFiling Source: edgar
Filing Date: May, 25 2016



Daily Technical Chart for (OTC: CHMP)

Daily Technical Chart for (OTC: CHMP)

Stay tuned for daily updates and more on (OTC: CHMP)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: CHMP)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

OTC Report



Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CHMP is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of CHMP and does not buy, sell, or trade any shares of CHMP. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: